hVIVO plc (LON:HVO – Get Free Report) shares were up 11.9% during mid-day trading on Friday . The company traded as high as GBX 7.50 and last traded at GBX 7.50. Approximately 4,541,654 shares changed hands during mid-day trading, an increase of 59% from the average daily volume of 2,858,300 shares. The stock had previously closed at GBX 6.70.
Wall Street Analyst Weigh In
A number of analysts have commented on HVO shares. Stifel Nicolaus restated a “hold” rating and set a GBX 10 price target on shares of hVIVO in a research note on Thursday, May 7th. Shore Capital Group reaffirmed a “buy” rating on shares of hVIVO in a research note on Wednesday, April 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of GBX 15.
View Our Latest Research Report on HVO
hVIVO Stock Performance
hVIVO Company Profile
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.
Featured Articles
- Five stocks we like better than hVIVO
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for hVIVO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for hVIVO and related companies with MarketBeat.com's FREE daily email newsletter.
